Ligand has assembled one of the largest portfolios of biopharmaceutical assets among our peers which provides investors the opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.
| Program | Partner | Indication | Technology | Development Stage | ||||
|---|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 or Regulatory | Approved | ||||
| Cangaroo Envelope | Aziyo | Medical Device | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Aziyo Base Business | Aziyo | Medical Device | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Carnexiv | Lundbeck | CNS | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Viviant/Conbriza | Pfizer | Inflammatory/Metabolic | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Duavee | Pfizer | Inflammatory/Metabolic | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| ZULRESSO | SAGE | CNS | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Kyprolis | Amgen | Oncology | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Exemptia | Zydus Cadila | Inflammatory/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Posaconazole | Par Pharmaceuticals | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Vfend-IV | Pfizer | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Voriconazole | Hikma | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Voriconazole | Alvogen | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Evomela | Spectrum | Oncology | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Nexterone | Baxter | Cardiovascular | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Noxafil-IV | Merck | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Bryxta | Zydus Cadila | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Baxdela | Melinta | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| Vivitra | Zydus Cadila | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory Complete
|
Approved In Progress
|
| CE-Fosphenytoin | Sedor | CNS | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| Reproxalap | Aldeyra Therapeutics | Other/Undisclosed | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| CHS-0214 | Coherus | Inflammatory/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| BCD-066 | Biocad | Blood Disorders | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| Pevonedistat | Takeda | Oncology | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| ONS-1045 | Oncobiologics | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| ONS-3010 | Oncobiologics | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| CS-3150 | Exelixis/Daiichi-Sankyo | Cardiovascular | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 Complete
|
Phase 3 or Regulatory In Progress
|
Approved Not Started
|
| MM-121 | Merrimack Pharma | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Lasofoxifene | Sermonix | Inflammatory/Metabolic | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| GS-5734 | Gilead | Infectious Disease | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| MM-141 | Merrimack Pharma | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Lubricin | Novartis | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Ganaxalone IV | Marinus Pharma | CNS | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Ensituximab | Precision Biologics | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OPT-302 | Opthea Ltd | Other/Undisclosed | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| hCDR1 | XTL Bio | Cardiovascular | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| VK5211 | Viking | Inflammatory/Metabolic | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| VK0612 | Viking | Inflammatory/Metabolic | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Sparsentan | Retrophin | Cardiovascular | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| KLM465 | Novartis | Blood Disorders | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| VTX-2337 | VentiRx Pharma | Oncology | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| TR Beta | Viking | Inflammatory/Metabolic | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Merestinib | Eli Lilly | Oncology | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| RVT-1502 | Roivant | Inflammatory/Metabolic | Other/NCE |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Prexasertib | Eli Lilly | Oncology | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| BMS986231 | BMS | Cardiovascular | Captisol |
Preclinical Complete
|
Phase 1 Complete
|
Phase 2 In Progress
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OPC-108459 | Otsuka | Cardiovascular | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| GNR-008 | IBC Generium | Cardiovascular | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Cudafol | Cuda Pharma | CNS | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| VTX-1463 | VentiRx Pharma | Oncology | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CXCR4 | Upsher-Smith | Oncology | Other/NCE |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| TAK-020 | Takeda | Inflammatory/Metabolic | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Mekinist POS | Novartis | Oncology | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| anti-FcRN | Hanall | Inflammatory/Metabolic | OmniAb |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| PCSK-9 | Genekey Biotech | Inflammatory/Metabolic | OmniAb |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| RGB-03 | Gedeon Richter | Inflammatory/Metabolic | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| IV Topiramate | CURx Pharma | CNS | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Pradefovir | Chiva Pharma | Infectious Disease | Other/NCE |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| F-102 | F-Star | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| MB07133 | Chiva Pharma | Oncology | Other/NCE |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| AMG-330 | Amgen | Oncology | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| ML-061 | Meridian | Oncology | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Trastuzumab | Gedeon Richter | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| PDL-1 | C-Stone | Oncology | OmniAb |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| PD-1 | Gloria | Oncology | OmniAb |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| BCMAxCD3 | Janssen | Oncology | OmniAb |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| JPH-203 (Injection) | J-Pharma | Oncology | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Deplera | IBC Generium | Oncology | Selexis SUREtechnology |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| ME-344 | MEI Pharma | Oncology | Captisol |
Preclinical Complete
|
Phase 1 In Progress
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| IRAK4 | TG Therapeutics | Oncology | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Lasofoxifene | Azure | Inflammatory/Metabolic | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CE-Budesonide | Sedor | Inflammatory/Metabolic | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CE-Meloxicam | Sedor | Inflammatory/Metabolic | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| anti-FcRN | Roivant | Inflammatory/Metabolic | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| anti-FcRN | Harbour | Inflammatory/Metabolic | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Tetragenics | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CRTH2 Antagonist | Seelos | Inflammatory/Metabolic | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Teva | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Tizona | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | WuXi | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | xCella | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| NUC-202 | Nucorion | Infectious Disease | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| SAGE-689 | SAGE | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| IV Lamotrigine | CURx Pharma | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CE-Acetaminophen | Seelos | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| PD-1 | Arcus | Oncology | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| EPOR Agonist | Viking | Blood Disorders | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CE-Ziprasodone | Beloteca | CNS | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Teneobio | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| DGAT-1 Inhibitor | Viking | Inflammatory/Metabolic | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CE-Cannabinoids | Vireo Health | Inflammatory/Metabolic | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| Undisclosed | AiCuris GmBH | Infectious Disease | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| NUC-101 | Nucorion | Infectious Disease | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| H3 Receptor Antagonist | Seelos | Inflammatory/Metabolic | Other/NCE |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Janssen | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CE programs | Avion | Other/Undisclosed | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | ARMO Biosciences | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Bluebird | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Boehringer Ingelheim | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Celgene | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Aptevo | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Amgen | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | ABBA | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | AbbVie | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Achaogen | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Alexo | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Ferring | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Five Prime Therapeutics | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Ono Pharmaceuticals | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Merck KGaA | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Pfizer | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Seattle Genetics | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Surface Oncology | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| CE-program | Interventional Analgesix | Other/Undisclosed | Captisol |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Hanall Biopharma | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | F-Star | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Genmab | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Gilead | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Glenmark | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
| OmniAb | Symphogen | Other/Undisclosed | OmniAb |
Preclinical In Progress
|
Phase 1 Not Started
|
Phase 2 Not Started
|
Phase 3 or Regulatory Not Started
|
Approved Not Started
|
